MedTech Innovator

Founded in 2019, Promedius specializes in developing innovative solutions for the early detection and management of musculoskeletal diseases like osteoporosis. Its flagship product, PROS® CXR:OSTEO, uses AI to analyze chest X-ray images, enabling healthcare providers to identify patients at risk of osteoporosis.

Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.

iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.

AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

RNT Health Insights develops an AI-assisted software as a medical device (SaMD) solution for early gastric cancer detection. This technology, granted FDA Breakthrough Device Designation, improves efficiency and accuracy in real-time during endoscopic procedures, with preclinical validation showing 96% accuracy in detecting lesions indicative of gastric cancer.

CardioSignal develops innovative solutions for detecting heart diseases. Its flagship product is a mobile application certified as a medical device for atrial fibrillation detection, built on over a decade of research.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

IFPx develops an implantable patient monitoring device that directly analyzes fluid buildup in the body. This device aims to improve the management of chronic illnesses, initially focusing on heart failure.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

NXgenPort develops digital health technology for remote monitoring of cancer patients between chemotherapy visits. Its Smart Port device measures cell counts and heart function in vivo, alerting physicians to signs of infection and reducing hospitalizations. This data also improves patient outcomes and provides valuable insights for cancer researchers.

Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.

SafeBeat Rx is a technology company specializing in advanced electrocardiogram solutions aimed at enhancing cardiac care. The company has developed software that facilitates remote patient monitoring, continuous telemetry, and event monitoring, significantly reducing the need for prolonged hospital stays for cardiac patients. By leveraging automated artificial intelligence, SafeBeat Rx's technology allows for safe medication initiation for arrhythmia patients while enabling effective monitoring of cardiac implantable electronic devices. This innovative approach expands access to cardiac care, allowing patients to receive essential services from the comfort of their homes.

CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.

Augment Health is a company focused on developing noninvasive medical devices and artificial intelligence algorithms to enhance the management of bladder dysfunction, particularly for the 7 million patients affected by neurologic disease or injury. The company's innovative technology allows for monitoring urine levels through a device that can be attached to catheters, providing timely notifications to users or care providers when the catheter reaches capacity. This approach aims to shift bladder diagnostics from clinical settings to patients' homes, addressing the high rate of inconclusive test results associated with traditional in-clinic diagnostics. By enabling better bladder health management, Augment Health seeks to prevent complications such as bladder muscle atrophy, ultimately improving the quality of life for patients.

LiveMetric is a medical device company focused on developing innovative, non-invasive sensing and deep data analytics solutions aimed at improving the management of hypertension and cardiovascular diseases. The company offers a wearable, cuff-free device for blood pressure monitoring that is FDA-cleared and validated for accuracy against traditional arterial line methods. This technology provides high-fidelity arterial pressure waveforms and continuous tracking of vital signs, allowing for real-time feedback and analysis for patients, physicians, and healthcare providers. By delivering personalized data and detailed activity mapping, LiveMetric aims to empower individuals, payors, self-insured employers, and healthcare providers, ultimately enhancing the care and quality of life for over one billion people worldwide affected by these conditions.

Founded in 2015, Gravitas Medical specializes in developing personalized automated nutrition management systems for hospitals. Its innovative nasogastric feeding system directly assesses feeding readiness and optimizes nutrition delivery, aiming to improve patient health outcomes while reducing cost-of-care and nursing burden.

Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.

PercuSense develops minimally invasive sensors for real-time tracking of multiple biochemicals. Their technology enables simultaneous detection of various analytes through a single probe, eliminating the need for manual calibration. By integrating artificial intelligence-based signal analysis, PercuSense facilitates early identification of metabolic dysfunction and other clinically significant conditions.

Darmiyan develops a SaaS platform, BrainSee, for early detection and monitoring of neurodegenerative diseases like Alzheimer's. Using standard MRI scans and cognitive tests, BrainSee generates detailed brain maps and scores indicating neurodegeneration, enabling timely diagnosis and intervention.

CU-BX is a health analytics platform focused on enhancing driver safety and comfort through advanced monitoring solutions. The company specializes in providing high-accuracy measurements of various health parameters, including fatigue, stress, heart rate, and respiratory rate. Its patented technology ensures reliable performance across diverse road and lighting conditions and is adaptable to various clothing and accessories. CU-BX collaborates with major automotive stakeholders, including original equipment manufacturers and suppliers, to develop driver monitoring systems and aftermarket solutions. By integrating sophisticated sensors and dashcam data, CU-BX aims to improve in-cabin comfort and promote safer driving practices, making it a key player in the automotive health analytics sector.

Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.

OpiSafe is a provider of platforms that manage the opioid response for various stakeholders, including prescribers, dispensers, public health agencies, first responders, and the general public. The company offers an opioid intelligence system designed to optimize prescriptions and improve healthcare outcomes. Its technology facilitates communication between patients and their care providers through a mobile application, allowing for more effective recovery and enhanced patient care. OpiSafe aims to bridge the gap between the opioid epidemic and the necessary solutions to address it.

PreDxion Bio is an early-stage healthcare company revolutionizing testing and treatment through low-cost, user-friendly at-home diagnostics. Enabled by PreDxion’s proprietary multiplexed localized surface plasmon resonance (LSPR) technology, our first product is a rapid, saliva-based test for COVID-19, flu, pneumonia, common cold, and other respiratory diseases.

Tueo Health is dedicated to improving asthma management, particularly for children. The company has developed an innovative solution that combines accurate, objective indicators of asthma control with clinical insights tailored to the needs of patients and their families. This system includes a contactless sensor designed to monitor and manage asthma effectively, allowing users to track treatment progress and outcomes. By focusing on these aspects, Tueo Health aims to enhance the quality of life for those living with asthma.

Adult Medical Predictive Devices, Diagnostics and Displays, Inc. (AMP3D) is a healthcare technology company that has developed a predictive analytics platform aimed at improving patient outcomes through early intervention. The platform analyzes real-time data from physiological monitoring and electronic health records using patented algorithms to forecast potentially catastrophic medical events, such as respiratory failure, hemorrhage, and severe sepsis. By enabling healthcare providers to anticipate these critical situations, AMP3D aims to reduce complications, length of hospital stays, and associated costs. The company intends to market its platform as a service on a value-based pricing model, targeting quality measures and performance standards that influence reimbursement. With the potential for significant cost savings—illustrated by a possible $600,000 annual savings from a 20% reduction in emergency intubations in a single ICU—AMP3D is positioned to address a substantial market opportunity within the inpatient healthcare sector.

MedAware develops innovative solutions using big data analytics and machine learning algorithms to analyze electronic medical records. Its patent-pending technology identifies and eliminates prescription errors in real-time, improving patient safety and reducing healthcare costs. Founded in 2012, MedAware is headquartered in Raanana, Israel.

TinyKicks is a technology company headquartered in Irvine, California, founded in 2014 by France Helfer. The company specializes in developing a wireless smart sensor system that captures fetal movement using machine learning to promote healthy pregnancy outcomes. Its flagship product, the TinyKicks eMotion fetal activity monitor, is a wearable device that detects the user's baby kicks, distinguishing them from the mother's movements. This continuous monitoring provides real-time data, which is automatically uploaded to the user's smartphone. The system utilizes machine learning algorithms to identify abnormal fetal movement, enabling pregnant women to receive timely notifications about potential complications, thereby reducing costs associated with pregnancy-related issues and enhancing overall pregnancy health tracking.